rss
Br J Ophthalmol 2006;90:1152-1156 doi:10.1136/bjo.2006.095141
  • Clinical science
    • Extended reports

Phase I clinical trial results of verteporfin enhanced feeder vessel therapy in subfoveal choroidal neovascularisation in age related macular degeneration

  1. I Kozak,
  2. L Cheng,
  3. D E Cochran,
  4. W R Freeman
  1. Jacobs Retina Center, University of California San Diego, Shiley Eye Center, La Jolla, CA, USA
  1. Correspondence to: Igor Kozak MD, University of California San Diego, Shiley Eye Center, 0946, 9415 Campus Point Drive, La Jolla, CA 92037, USA; ikozak{at}eyecenter.ucsd.edu
  • Accepted 4 June 2006
  • Published Online First 14 June 2006

Abstract

Aims: To investigate the safety and effectiveness of extrafoveal photodynamic therapy (PDT) occlusion of feeder vessels (FVs) in patients with subfoveal choroidal neovascularisation (CNV) as a result of age related macular degeneration.

Methods: FVs were identified using dynamic fluorescein and indocyanine green angiography with scanning laser ophthalmoscope. The standard doses of verteporfin and laser wavelength were used. The light dose was escalated by increasing the duration of the light dose so the light regimen was 50 J/cm2 for patients 1 and 2; 100 J/cm2 for patients 3, 4, 5; 125 J/cm2 for patients 6 and 7; and 150 J/cm2 for patients 8 and 9. Patients were examined at weeks 1, 4, and 12.

Results: The mean improvement on EDTRS chart 3 months after treatment was an increase of 2.1 lines (p = 0.07). Closure of the FV was achieved angiographically in three eyes at various light doses, in three eyes the FV was hypoperfused, and in three eyes the vessels were were neither closed nor hypoperfused. At the last follow up all FVs were reperfused. There was no evidence of retinal damage.

Conclusion: Verteporfin enhanced FV therapy does not cause subfoveal retinal damage and may have potential to improve central vision in subfoveal CNV caused by exudative macular degeneration. It is not recommended as a monotherapy for CNV.

Footnotes

  • Financial disclosure: none.

    Support: QLT Inc Vancouver donated the verteporfin used for this study.

This Article

  1. Abstract
  2. Full text
  3. PDF
  4. All versions of this article:
    1. bjo.2006.095141v1
    2. 90/9/1152 most recent

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.